Nephrocare Health Faces ₹14.79 Crore Uzbekistan Tax Demand

Nephrocare Health Services Limited faces aggregate exposure of approximately ₹14.79 crore after Uzbekistan’s Tashkent City Tax Department assessed additional tax and a penalty at its wholly owned subsidiary for the 2023-25 audit period. The company says the matter stems from a revenue-data reconciliation issue and expects no material adverse impact.

Why did Nephrocare Health receive a tax assessment in Uzbekistan?

Nephrocare Health’s wholly owned subsidiary, Nephrocare Health Services Central Asia LLC, received a tax audit order from the Tashkent City Tax Department on August 31, 2026. The order relates to Decision No. 721.1, dated August 24, 2026, following an audit of the subsidiary’s operations from January 1, 2023, to December 31, 2025.

The assessment concerns the subsidiary’s eligibility for a corporate income-tax exemption available to income from dialysis and related medical services. Under the cited Uzbekistan tax framework, the exemption applies when qualifying medical-service income exceeds 90% of total revenue. The subsidiary operates exclusively in dialysis services, and the Ministry of Health is its primary payor.

Nephrocare Health said its audited records show that dialysis revenue exceeded the required threshold. However, it said the revenue figures considered by the tax department appeared to differ from payment data provided by the Ministry of Health and from its own audited records. The company has described the issue as a data-reconciliation discrepancy rather than a failure to meet the exemption conditions.

What is the breakup of Nephrocare Health’s ₹14.79 crore exposure?

Nephrocare Health’s disclosed aggregate exposure is approximately ₹14.79 crore, comprising a net additional tax assessment of about ₹11.50 crore and a financial penalty of about ₹3.29 crore. The amount does not include applicable late-payment interest.

The tax department initially assessed additional taxes of UZS 20,371,068,018, or approximately ₹16.50 crore. It subsequently allowed reductions of UZS 6,167,012,658, or approximately ₹4.99 crore, resulting in a net tax assessment of UZS 14,204,055,360. The penalty of UZS 4,064,086,532 was imposed under Article 224 of the applicable tax law.

The company noted that late-payment interest under Article 110, if applicable, is excluded from the disclosed aggregate figure. This means the reported ₹14.79 crore represents the tax and penalty identified in the assessment, rather than a final amount including any future interest calculation.

What steps is Nephrocare Health taking against the Uzbekistan order?

Nephrocare Health is reconciling the underlying revenue data with the Uzbekistan tax department and is evaluating available legal remedies, including an appeal. As of the company’s disclosure date, no appeal or other legal proceeding had been initiated.

The company has stated that it believes the order should be set aside or quashed. Its position is based on the audited revenue records and preliminary Ministry of Health data that it says support the subsidiary’s eligibility for the tax exemption.

The order becomes effective one month after it is presented to the taxpayer. That timing makes the reconciliation process and any decision on a formal appeal important near-term developments. The company has not disclosed a final resolution date or the exact form of legal action it may pursue.

How does the Uzbekistan issue affect Nephrocare Health’s operations?

Nephrocare Health has said it does not expect the assessment to have a material adverse effect on its financial position, operations, or business. The company has framed the matter as an isolated overseas regulatory issue tied to administrative revenue records rather than to the delivery of dialysis services.

The company provides dialysis and related healthcare services and products through a network of approximately 490 clinics. It has 43 international clinics across the Philippines, Uzbekistan and Nepal. The Uzbekistan subsidiary is part of this overseas network, making the audit relevant to the company’s international operations even though the assessment relates specifically to one jurisdiction.

For investors, the disclosed exposure is a defined liability under dispute rather than a confirmed cash outflow. The financial significance will depend on whether the tax authority accepts the data reconciliation, whether Nephrocare Health files an appeal, and whether interest becomes payable. The company’s statement that it expects no material impact is its assessment, not a resolution of the order.

Why is the tax-exemption threshold central to the dispute?

The central issue is whether more than 90% of the subsidiary’s total revenue qualified as income from dialysis and related medical services. That threshold determines whether the subsidiary can claim the corporate income-tax exemption cited in the tax assessment.

Nephrocare Health maintains that the subsidiary’s business is exclusively dialysis-focused and that its audited records satisfy the threshold. The tax department’s assessment, according to the company, appears to rely on revenue figures that do not align with its records or with preliminary payment data from the Ministry of Health.

The case therefore turns on the reconciliation of information used by the taxpayer, the healthcare payor and the tax authority. Until the company completes that process or begins formal appellate proceedings, the assessment remains an unresolved regulatory matter for the Uzbekistan unit.

Conclusion

The ₹14.79 crore Uzbekistan assessment places a specific tax and penalty exposure on Nephrocare Health’s overseas subsidiary. The disclosed issue concerns differing revenue data used to assess eligibility for a dialysis-services tax exemption, while the company maintains that its audited records support its exemption claim.

The next development to watch is whether Nephrocare Health completes a reconciliation with the Tashkent City Tax Department or files an appeal before the order becomes effective one month after presentation to the taxpayer. Investors will also watch for any update on late-payment interest or a revised assessment amount.